Zheng Y - Search Results

1

Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204).

Zheng Y, Zhu J, Xiong J, Jiang O, Wang H, Xie Y, Zhou Y, Xu N. Zheng Y, et al. Cancer. 2024 Jun 15;130(12):2180-2190. doi: 10.1002/cncr.35259. Epub 2024 Feb 27. Cancer. 2024. PMID: 38412283 Clinical Trial.

2

Primary primitive neuroectodermal tumor of the urinary bladder: a case report and literature review.

Zheng Y, Tan F, Wang L, Xu N, Mou H. Zheng Y, et al. Med Oncol. 2011 Dec;28 Suppl 1:S388-91. doi: 10.1007/s12032-010-9680-3. Epub 2010 Sep 18. Med Oncol. 2011. PMID: 20852971 Review.

3

Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.

Fang WJ, Mou HB, Jin DZ, Zheng YL, Zhao P, Mao CY, Peng L, Huang MZ, Xu N. Fang WJ, et al. Oncol Rep. 2012 May;27(5):1606-10. doi: 10.3892/or.2012.1678. Epub 2012 Feb 7. Oncol Rep. 2012. PMID: 22322240

4

Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.

Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N. Peng L, et al. Among authors: zheng y. Mol Biol Rep. 2012 Oct;39(10):9473-84. doi: 10.1007/s11033-012-1812-8. Epub 2012 Jun 23. Mol Biol Rep. 2012. PMID: 22729879

5

New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.

Zheng Y, Fang W, Liu X, Xu N. Zheng Y, et al. Tumori. 2012 Jul-Aug;98(4):e102-4. doi: 10.1177/030089161209800422. Tumori. 2012. PMID: 23052173

6

Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature.

Zheng Y, Fang W, Xu N. Zheng Y, et al. Oncol Lett. 2012 Dec;4(6):1341-1343. doi: 10.3892/ol.2012.904. Epub 2012 Sep 10. Oncol Lett. 2012. PMID: 23205134 Free PMC article.

7

Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature.

Xu Q, Xu N, Fang W, Zhao P, Mao C, Zheng Y, Mou H. Xu Q, et al. Among authors: zheng y. Oncol Lett. 2013 May;5(5):1601-1604. doi: 10.3892/ol.2013.1232. Epub 2013 Mar 6. Oncol Lett. 2013. PMID: 23759738 Free PMC article.

8

Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?

Zheng Y, Xu N, Zhou J. Zheng Y, et al. Lancet Oncol. 2013 Oct;14(11):e438. doi: 10.1016/S1470-2045(13)70412-1. Lancet Oncol. 2013. PMID: 24079869 No abstract available.

9

Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis.

Deng J, You Q, Gao Y, Yu Q, Zhao P, Zheng Y, Fang W, Xu N, Teng L. Deng J, et al. Among authors: zheng y. PLoS One. 2014 Feb 21;9(2):e88907. doi: 10.1371/journal.pone.0088907. eCollection 2014. PLoS One. 2014. PMID: 24586437 Free PMC article. Review.

10

Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.

Zheng Y, Fang W, Mao C, Qian J, Zhao P, Zhang X, Jiang H, Zheng Y, Xu N. Zheng Y, et al. Cancer Chemother Pharmacol. 2014 Sep;74(3):503-9. doi: 10.1007/s00280-014-2537-2. Epub 2014 Jul 20. Cancer Chemother Pharmacol. 2014. PMID: 25038612 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37,467 results

Search Page

Filters